Taltz is approved to treat adults and children 6 years and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

Taltz affects the immune system. It may increase your risk of infections, which can be serious. Do not use Taltz if you have any symptoms of infection, unless your doctor tells you to. If you have a symptom after starting Taltz, call your doctor right away.

4 out of 10 adult patients taking Taltz achieved completely clear skin at 12 weeks. Illustration of 100% skin clearance at 12 weeks. Photos are for illustrative purposes only and do not depict actual patients. Individual results may vary.

Taltz can weaken part of your immune system and increase your risk for infection. This includes serious infections such as tuberculosis (TB). * Before starting Taltz, your doctor will test you for TB. It's also recommended that you get any vaccines that you need before starting treatment with Taltz.

After almost 6 months, more than 50% of people in either study receiving Taltz every 4 weeks had at least a 20% improvement in joint pain and swelling. In both studies, more than 20% of these same people experienced up to a 70% improvement in joint pain and swelling.

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

TALTZ is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Under this license, you are approved to manufacture TALTZ drug substance at Eli Lilly S.A. in, Dunderrow Kinsale, County Cork, Ireland.

Taltz can weaken part of your immune system and increase your risk for infection. This includes serious infections such as tuberculosis (TB). * Before starting Taltz, your doctor will test you for TB. It's also recommended that you get any vaccines that you need before starting treatment with Taltz.

4 out of 10 adult patients taking Taltz achieved completely clear skin at 12 weeks. Illustration of 100% skin clearance at 12 weeks. Photos are for illustrative purposes only and do not depict actual patients. Individual results may vary.

In patients withactive psoriatic arthritis (PsA), the use of ixekizumab (Taltz, Eli Lilly) is safe for up to 3 years, according to an analysis of data from 4 clinical trials with over 2000 patient-years of exposure.

No, Taltz isn't known to cause liver problems.

Warnings and precautions include infections, pre-treatment evaluation for tuberculosis, hypersensitivity, inflammatory bowel disease, and immunizations. The most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

How can Taltz help you with your symptoms? Some patients felt joint symptom relief in as early as 1 week. Individual results may vary. Of all the patients taking Taltz who achieved joint symptom improvement at 6 months, more than half maintained those results at 3 years with continued treatment.

Ixekizumab (Taltz(®)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis.

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.